Ongoing Clinical Trials for Congenital Generalised Lipodystrophy
Currently, there are 2 ongoing clinical trials studying treatments for congenital generalised lipodystrophy across several European countries. These trials are investigating how specific medications can help manage this rare condition where the body has difficulty storing fat properly, often leading to diabetes and other metabolic complications.
Clinical trial locations
- Austria
- Belgium
- France
- Germany
- Italy
- Poland
- Sweden
Study on Metreleptin for Children Under 6 with Generalized Lipodystrophy and Related Diabetes or High Triglycerides
This trial is investigating metreleptin as a treatment for young children with generalised lipodystrophy. The condition affects how the body stores fat, which can lead to serious complications like diabetes and dangerously high levels of fats in the blood.
Who can participate:
Children under 6 years old who have never been treated with metreleptin before may be eligible for this study. To qualify, children must have a confirmed diagnosis of generalised lipodystrophy through genetic testing, imaging tests showing very little body fat, or a clinical diagnosis with low leptin hormone levels and signs of insulin resistance. Additionally, children must have either high blood sugar levels or high triglyceride levels. If a child has diabetes, they should be on a stable treatment plan for at least 90 days before joining the study. Similarly, children with high triglyceride levels should be on stable treatment for at least 6 weeks. Parents or guardians must be able to provide informed consent and agree to follow all study requirements.
Who cannot participate:
Children who are 6 years of age or older cannot join this study. Additionally, children who do not have a diagnosis of generalised lipodystrophy, or who do not have associated diabetes or high triglyceride levels, are not eligible.
What the study involves:
The trial focuses on metreleptin, a hormone replacement therapy given as an injection under the skin. Metreleptin works by replacing leptin, a hormone that is usually low in people with this condition. The goal is to help control blood sugar levels and reduce fat levels in the blood. The study will last for 12 months, during which participants will receive regular metreleptin injections. Children will attend regular follow-up visits where healthcare professionals will monitor their health, including blood sugar and triglyceride levels, and assess any side effects. The study aims to understand whether metreleptin can improve the quality of life for young children with this rare condition.
Study on the Effect of Raxtozinameran Vaccine in Reducing Type 1 Diabetes Risk in Children with High Genetic Susceptibility
This clinical trial is investigating whether a COVID-19 vaccine can help reduce the risk of developing type 1 diabetes in children who have a high genetic risk for the disease. Type 1 diabetes occurs when the body’s immune system attacks the cells in the pancreas that produce insulin.
Who can participate:
Children between 3 and 4 months old at the time of joining may be eligible. To qualify, children must have a high genetic risk of developing islet autoantibodies by age 6. This risk is determined by specific genetic markers, a polygenic risk score, and having a close family member with type 1 diabetes. Parents or guardians must provide written informed consent after being fully informed about the study.
What the study involves:
The trial is studying the Comirnaty Omicron XBB.1.5 COVID-19 mRNA Vaccine, which uses a small piece of genetic material called mRNA to help the body recognize and fight the virus that causes COVID-19. The vaccine is given as an injection. Some participants will receive this vaccine, while others will receive a simple saline solution as a placebo. The study aims to see if the vaccine helps prevent the development of islet autoantibodies, which are markers indicating the immune system is attacking the pancreas, or type 1 diabetes itself during childhood. Children will have regular follow-up visits to monitor their health and assess the vaccine’s effectiveness. The study will continue until 2029 to gather enough information about the vaccine’s impact on preventing type 1 diabetes in high-risk children.
Summary
There are currently 2 clinical trials underway for congenital generalised lipodystrophy, spanning multiple European countries including Belgium, France, Germany, Italy, Austria, Poland, and Sweden. The first trial specifically targets children with generalised lipodystrophy and is investigating metreleptin, a hormone replacement therapy designed to address the metabolic complications of the condition. This study is particularly focused on very young children under 6 years old who also have diabetes or high triglyceride levels.
The second trial takes a different approach by investigating whether early vaccination against COVID-19 might reduce the risk of developing type 1 diabetes in genetically susceptible infants. While this study focuses primarily on diabetes prevention rather than lipodystrophy treatment directly, it reflects the broader research interest in understanding and preventing the metabolic complications often associated with these conditions.
Both trials demonstrate the ongoing efforts to find better treatments for rare metabolic disorders in children, with a notable concentration of research activities in German-speaking countries and Belgium. The metreleptin trial represents a direct therapeutic approach to managing the condition, while the vaccine study explores preventive strategies for associated complications.
